ChrysCapital eyes stake in Linux Labs

By Sohail Khan 9 September 2026, 12:46 am

Benchmarks
Nifty23,635.10-144.06

Precious Metal
Gold (MCX) (Rs/10g.)152,605.00-213.0

Enter search text:

Business News›News›Company›Corporate Trends›Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake

Read Today's Paper

Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake
Synopsis

Private equity firm ChrysCapital is set to acquire a significant stake in Linux Laboratories. This deal will see existing investor Tata Capital Healthcare Fund exit its entire holding. Linux Laboratories focuses on central nervous system therapies and has a strong brand portfolio. The company anticipates robust revenue and Ebitda growth in the coming years. This acquisition highlights continued private equity interest in India's pharmaceutical sector.

pharma-new — Tata Capital Healthcare Fund to exit Linux Laboratories as ChrysCapital buys 20-25% stake

Mumbai: Homegrown private equity firm ChrysCapital is set to acquire a 20-25% stake in central nervous system (CNS)- focused domestic formulations company Linux Laboratories for around $60-65 million (₹600 crore), people aware of the development told ET. Tata Capital Healthcare Fund, an existing investor in Chennai-based Linux Laboratories, will exit its entire 15% stake as part of the transaction, while ChrysCapital will acquire an additional 5-10% stake through a primary capital infusion.

Presently, founders Keerthivasan K, Ananda Kumar Sundharam and Hariharan Parameswaran together hold 84.68%. Tata Capital Healthcare Fund II holds a 15.32%, Tracxn data showed. Tata Capital Healthcare Fund invested ₹80 crore in Linux in 2021.

Also read: Pharma sector must attract more investment in clinical trials, R&D: Piyush Goyal

Founded in 2007, Linux has a portfolio of more than 64 brands across around 180 products, spanning therapeutic segments such as neurology, psychiatry and cosmetic dermatology.

Linux Laboratories is expected to post a revenue of ₹450-500 crore and an Ebitda of ₹85-90 crore in FY27, said sources.

Mails sent to Linux Laboratories and ChrysCapital remained unanswered until the publication of this report, while a Tata Capital spokesperson declined to comment. Private equity interest in India's pharmaceutical formulations sector has remained strong, particularly in domestic branded-generics businesses with established brands and exposure to chronic and specialtiy therapies.

ET Bureau

Big bet

In 2024, ChrysCapital invested about $70 million in La Renon Healthcare at a valuation of around $800 million, while the firm has also backed companies such as Mankind Pharma, Eris Lifesciences, Torrent Pharmaceuticals and Ipca Laboratories.

Kunal Shroff, managing partner at ChrysCapital, believes that geopolitical issues have a relatively limited impact on ChrysCapital's portfolios. In the pharma segment, most of the portfolio companies are domestically focused, and they continue to grow with strong margins and healthy returns on equity, he told ET last year. In July, ChrysCapital had acquired a controlling 70.68% stake in Novartis India (NIL), with major brands such as Voveran, Calcium Sandoz and Tegretol.

Since its inception in 1999, ChrysCapital has cumulatively raised close to $8.5 billion across 10 PE funds, a continuation vehicle, and its public markets fund. Through its PE funds, it has deployed over $5.5 billion in more than 110 portfolio companies.

Also read: Sun Pharma gets ratings boost from Moody's, S&P over USD 11.75-bn Organon & Co acquisition bid

The Indian pharmaceutical industry ranks 3rd globally by volume and 11th by value. The domestic pharmaceutical market, valued at $60 billion, is projected to reach $130 billion by 2030, according to the Government of India. India is the largest global supplier of generic medicines, accounting for around 20% of global supply, manufacturing 60,000 generic brands across 60 therapeutic categories.

Add as a Reliable and Trusted News Source
Add Now!

(You can now subscribe to our WhatsApp channel)

(You can now subscribe to our WhatsApp channel)

Read More News on
ChrysCapital investmentLinux Laboratories acquisitionprivate equity in pharmaceuticalsTata Capital Healthcare FundIndian pharmaceutical market growthhealthcare investment Indiaipca laboratorieseris lifesciencestorrent pharmaceuticals

Enter search text:

Continue reading with one of these options:
Limited Access
Free
Login to get access to some exclusive stories

& personalised newsletters
Login Now

Unlimited Access
Starting @ Rs120/month
Get access to exclusive stories, expert opinions &

in-depth stock reports
Subscribe Now

Unlock Access to All Exclusives with ETPrime FREE TRIAL

15 Days Free: Unlock All ETPrime Exclusives, Market Tools & ePapers

Trial offer expiring in00 : 05 : 00

I'd rather pay ₹2599 now

Uh-oh! This is an exclusive story available for selected readers only.

Worry not. You’re just a step away.

Prime Account Detected!

It seems like you're already an ETPrime member with

Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Unlock ETPrime's Exclusive Stories Today!

Subscribe to gain powerful insights on business, stock market and industry trends.

Big Price Drop! Flat 40% Off

Student Only Offer

Already a Member? Sign In now

Already a Member? Sign In now
Already a Member? Sign In now

Offer Exclusively For You

Save up to Rs. 700/-

ON ET PRIME MEMBERSHIP

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get 1 Year Free

With 1 and 2-Year ET prime membership

Avail Offer

Offer Exclusively For You

Get Flat 40% Off

Then ₹ 1749 for 1 year

Avail Offer

Offer Exclusively For You

ET Prime at ₹ 49 for 1 month

Then ₹ 1749 for 1 year

Avail Offer

Special Offer

Get flat 40% off on ETPrime

Avail Offer
Avail Offer

Claim NowAlready a Member? Sign In now

Need Assistance?

Connect with an ETPrime expert for personalized support and guidance

+91 9484700004

' + h3 + '

' + h4 + '

' + listing + '

What’s Included with

ETPrime Membership

1Exclusive Insights That Matter

Uncover the truth with our investigative stories

Make strategic moves using the real-world case studies

Read industry-specific stories to identify emerging trends

Spot opportunities with in-depth insights that matter

Trump temper on H-1B visas is forcing Indians to do these things to stay put in US

What Adani’s US indictment means for India Inc’s overseas fundraising
Why veterans like Reliance, L&T are on acquisition spree? Aswath Damodaran has an answer.

Will China’s dollar bond sale in Saudi Arabia trump the US in financial world?
Huawei launches its own OS to compete with Google and Apple. But can it win beyond China?

The problem with lab grown diamonds
Why a falling rupee is a better option for the economy

A list of top 20 momentum stocks that have delivered massive returns in one year